Hidradenitis Suppurativa: Clinical, hormonal and molecular markers associated with clinical response to IL-23 antagonism – A Prospective Cohort Study

PD-1 inhibitor induced skin reactions

Real-world evidence for guselkumab treatment of severe psoriasis: A sub-group analysis of efficacy and drug survival from the Australasian Psoriasis Registry

Resistant case of pressure induced urticaria treated with Adalimumab

Effectiveness of biologics in clinical practice in Australian patients: Week 12 primary outcomes from the international observational psoriasis study of health outcomes (PSoHO)

Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial

Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension

Bimekizumab early responses in patients with plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial

Bimekizumab early treatment response translates into cumulative health-related quality of life benefits in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials

Bimekizumab efficacy and safety through 2 years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials

Trade-offs and decision making in moderate to severe psoriasis for oral vs. injectable treatments: Data from Australian patients and dermatologists

Cumulative clinical benefit of treatment initiation with deucravacitinib vs. apremilast over 52 weeks for patients with moderate to severe plaque psoriasis in the POETYK PSO-1 trial